Articles By Wayne Koberstein, Executive Editor
-
![D. Treco Headshot - Cropped]( "State Of The Orphan Space")
State Of The Orphan Space3/1/2024Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing practices.
-
![Kristine Ball Headshot 2023]( "Companies To Watch: Antiva Biosciences")
Companies To Watch: Antiva Biosciences2/27/2024Antiva Biosciences is exploring a local and global opportunity with a topically administered HPV treatment.
-
![Robert Fallon, President & CEO, Promontory Tx]( "Companies to Watch: Promontory Therapeutics")
Companies to Watch: Promontory Therapeutics2/1/2024A novel small molecule developer aims to shake up the solid tumor treatment landscape.
-
![Park_Jason_Flagship + Empress (1)]( "Empress Builds Base for Small-Molecule Innovation")
Empress Builds Base for Small-Molecule Innovation2/1/2024Empress, launched by Flagship Pioneering, aims to harness AI and evolutionary biology to design the next generation of small molecule therapies.
-
![Bruce Leuchter]( "Neurvati Maps Path To Neuroscience Approvals")
Neurvati Maps Path To Neuroscience Approvals1/1/2024Can a nested financial model help bring the next generation of neuroscience treatments to patients?
-
![Chris Hoyt_Companies To Watch_Jan]( "Companies To Watch: KeifeRx")
Companies To Watch: KeifeRx1/1/2024Founded in late 2019, KeifeRx is repurposing oncology drugs for neurodegenerative disorders.
-
![Biopharma’s Eminent Challenges Feature]( "Biopharma’s Eminent Challenges In 2024 — Inside & Out")
Biopharma’s Eminent Challenges In 2024 — Inside & Out12/1/2023A baker’s dozen of biopharma CEOs answer a call to prioritize and describe challenges they expect to face in the coming year.
-
![Cardior_450X300]( "Heading Back Home To The Heart")
Heading Back Home To The Heart11/1/2023Cardior Pharmaceuticals, led by CEO and cofounder Claudia Ulbrich, is developing what may be a much broader approach to heart failure, one that seeks to restore the diseased heart to its natural healthy state.
-
![CtW_Freya Bioscieneces _450x300]( "Companies To Watch: Freya Biosciences")
Companies To Watch: Freya Biosciences11/1/2023Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.
-
![Scott Braunstein_450x300]( "Rescuing A Company’s Core Purpose")
Rescuing A Company’s Core Purpose10/2/2023When Dr. Scott Braunstein moved from his position as chairman of the board and interim CEO to become permanent CEO of Marinus Pharmaceuticals in August 2019, he had already concluded an overbroad focus was holding the company back.
-
![CtW - Spruce_Javier_450x300]( "Companies To Watch: Spruce Biosciences")
Companies To Watch: Spruce Biosciences10/2/2023Spruce Biosciences is currently in mid-to-late stage clinical development of new agents to treat rare endocrine disorders.
-
![CtW - Nido Bio_450x300]( "Companies To Watch: Nido Biosciences")
Companies To Watch: Nido Biosciences9/1/2023See why Nido Biosciences is developing small molecule drugs for rare neurodegenerative diseases.
-
![TRIS PHARMA_450x300]( "To America, A New Biopharma Model")
To America, A New Biopharma Model9/1/2023Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses — platform technology licensing, generic medicines, and new drug development.
-
![CtW_Kurt Harrington_Ventoux_450x300]( "Companies To Watch: Ventoux Biosciences")
Companies To Watch: Ventoux Biosciences8/1/2023Why Ventoux Biosciences is pursuing drug treatments for all sufferers of Dupuytren’s and other fibroproliferative diseases.
Wayne Koberstein
Click here to e-mail Wayne
Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.